Press Releases

Date	Title and Summary	Additional Formats
Toggle SummaryJan 23, 2024	The Biden-Harris Administration Announces New Guidance to Enable Expanded Access to All FDA-Approved Contraceptives Without Cost Implementation of the New Guidance Could Eliminate Financial Barriers for Contraceptive Products like Twirla ® for 49 Million Women These Actions Follow Several Months of Activity by the Biden Administration to Strengthen Access to All FDA Approved Contraceptives as Defined in President Biden’s...	PDF Version
Toggle SummaryNov 1, 2012	Phase III Data Show Greater Compliance Across Demographic Groups With Agile Therapeutics' Contraceptive Patch Compared to an Oral Contraceptive
Toggle SummarySep 24, 2012	Phase III Data Show Agile Therapeutics’ Contraceptive Patch had Greater Compliance than an Oral Contraceptive
Toggle SummaryApr 25, 2012	New Studies on Agile Therapeutics’ Low-Dose Contraceptive Patch to be Presented at the American College of Obstetricians and Gynecologists’ Annual Clinical Meeting
Toggle SummaryMay 7, 2012	New Phase III Data Show Agile Therapeutics’ Low-Dose Patch is Comparable to Combination Oral Contraceptive in a Comparator Study
Toggle SummaryJul 24, 2018	FDA’s Office of Drug Evaluation III Denies Agile Therapeutics, Inc.’s Initial Formal Dispute Resolution Request Company Plans to Appeal to the FDA’s Office of New Drugs PRINCETON, N.J. , July 24, 2018 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq:AGRX) (the “Company”), a women’s healthcare company, today announced that the Office Director of the FDA’s Office of Drug Evaluation III (ODEIII) has...	FDA’s Office of Drug Evaluation III Denies Agile Therapeutics, Inc.’s Initial Formal Dispute Resolution Request 23.4 KB
Toggle SummaryFeb 14, 2020	FDA Approves Agile Therapeutics, Inc.’s Twirla® (levonorgestrel and ethinyl estradiol) Transdermal System – A New Weekly Contraceptive Patch Delivering a 30 mcg Daily Dose of Estrogen and 120 mcg Daily Dose of Progestin Twirla ® is a new non-daily, non-invasive contraceptive approved in the U.S. PRINCETON, N.J. , Feb. 14, 2020 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. , (Nasdaq: AGRX) (Agile or the Company), a forward-thinking women’s healthcare company, today announced that the U.S....	PDF Version
Toggle SummaryMay 6, 2013	Data on Agile Therapeutics' Low-Dose Contraceptive Patch (AG200-15) Presented at American College of Obstetricians and Gynecologists' (ACOG) Annual Clinical Meeting
Toggle SummaryMay 6, 2013	Data on Agile Therapeutics Low-Dose Contraceptive Patch (AG200-15) Presented at the First Global Conference on Contraception, Reproduction and Sexual Health Organized by the European Society of Contraception and Reproductive Health (ESCRH)
Toggle SummaryMar 21, 2024	Correction - Agile Therapeutics to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on Thursday, March 28, 2024 Live Conference Call and Webcast at 8:30 a.m. ET PRINCETON, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2023 financial results before the market opens on Thursday, March...	PDF Version